Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Session 2 – Targeting KRAS G12C in Lung Cancer

Resistance to KRAS G12C Inhibitors – What Do We Know?

Date

13 Oct 2021

Session

Session 2 – Targeting KRAS G12C in Lung Cancer

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

G. Dy, US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

13 Oct 2021

Clinical Development of KRAS G12C Inhibitors – Where Are We Now?

Presenter: P. Janne, US

Session: Session 2 – Targeting KRAS G12C in Lung Cancer

Resources:

Slides

Webcast

13 Oct 2021

Moving Forward with KRAS G12C Inhibitors – Combinations, Sequencing, Early stage

Presenter: C. Lindsay, UK

Session: Session 2 – Targeting KRAS G12C in Lung Cancer

Resources:

Slides

Webcast

13 Oct 2021

Clinical Cases and Expert Panel Discussion: Single Agent Case with Liver Toxicity

Presenter: G. Pasello, IT

Session: Session 2 – Targeting KRAS G12C in Lung Cancer

Resources:

Slides

Webcast

13 Oct 2021

Clinical Cases and Expert Panel Discussion: Combination Therapy

Presenter: C. Bestvina, US

Session: Session 2 – Targeting KRAS G12C in Lung Cancer

Resources:

Slides

Webcast